Nuclease-Resistant Oligonucleotide for Nidovirus Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are ineffective for treating coronavirus infections, particularly severe acute respiratory syndrome (SARS) caused by SARS-CoV, as no vaccines or effective antiviral therapies are available, leading to significant morbidity and mortality with limited treatment options.
Innovation Solution
Development of an oligonucleotide compound with a nuclease-resistant backbone, capable of uptake by virus-infected human cells, and complementary to specific sequences in the nidovirus genomic RNA, forming a heteroduplex structure that inhibits viral replication by disrupting transcriptional regulatory sequences.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antiviral therapies are used, then treatment options are limited, but they are ineffective for treating coronavirus infections
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of oligonucleotide compounds through various backbone modifications (phosphorodiamidate, phosphotriester, carbamate, carbonate linkages) and sugar modifications (2'-O-methyl, 2'-O-alkyl groups) to enhance nuclease resistance and cellular uptake while maintaining viral RNA binding affinity, thereby improving therapeutic effectiveness
Solution Approach 2:
The patent employs composite materials by combining modified nucleotide subunits with specific backbone linkages to create chimeric oligonucleotide compounds that integrate the benefits of different chemical structures - the stability of phosphorodiamidate linkages, the nuclease resistance of 2'-O-methyl modifications, and the cellular permeability of cationic groups
2Stability of the object's composition
If oligonucleotide compound is designed with nuclease-resistant backbone, then stability increases, but cellular uptake may be reduced
Solution Approach 1:
The patent applies local quality by strategically placing different chemical modifications at specific positions within the oligonucleotide sequence - for example, positioning cationic phosphorodiamidate linkages at terminal regions to enhance cellular uptake while maintaining stable phosphodiester or phosphotriester linkages in the central region to ensure nuclease resistance, thereby optimizing both properties locally throughout the molecule
Solution Approach 2:
The patent utilizes parameter changes by systematically varying the chemical parameters of the backbone linkages and sugar modifications to find the optimal balance between stability and uptake - adjusting the ratio of different linkage types, modifying the degree of 2'-O-alkylation, and changing the charge density of cationic groups to achieve both nuclease resistance and cellular permeability
3Reliability
If oligonucleotide compound forms stable heteroduplex with viral RNA, then viral replication is inhibited, but the compound must be taken up by cells effectively
Solution Approach 1:
The patent applies parameter changes by optimizing the melting temperature (Tm) of the heteroduplex through adjustments in oligonucleotide length, GC content, and chemical modifications while simultaneously modifying cellular uptake parameters through cationic group incorporation and backbone charge adjustment, achieving both strong viral RNA binding and effective cellular delivery
Solution Approach 2:
The patent employs intermediary mechanisms by using cell-penetrating peptides, lipid conjugates, or nanoparticle carriers as mediators that facilitate the entry of the oligonucleotide compound into cells while protecting it from degradation, thereby enabling both cellular uptake and subsequent viral replication inhibition
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The oligonucleotide compound effectively reduces viral titers and plaque size, inhibiting coronavirus replication and potentially treating SARS-CoV and other nidovirus infections by forming stable heteroduplexes with viral RNA, thereby mitigating the severity of the disease.
Implementation Method 1
having a sequence that is complementary to at least 8 bases contained in one of: (1) a sequence in a 5' leader sequence of the nidovirus' positive-strand genomic RNA... The compound is capable of forming with the nidovirus... a heteroduplex structure characterized by (1) a Tm of dissociation of at least 45°C
Data Source
AI summary
A method and oligonucleotide compound for inhibiting replication of a nidovirus in virus-infected animal cells are disclosed. The compound (i) has a nuclease-resistant backbone, (ii) is capable of uptake by the infected cells, (iii) contains between 8-25 nucleotide bases, and (iv) has a sequence capable of disrupting base pairing between the transcriptional regulatory sequences in the 5′ leader region of the positive-strand viral genome and negative-strand 3′ subgenomic region. In practicing the method, infected cells are exposed to the compound in an amount effective to inhibit viral replication.